P
Pinak B. Shah
Researcher at Brigham and Women's Hospital
Publications - 108
Citations - 5341
Pinak B. Shah is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Valve replacement & Medicine. The author has an hindex of 19, co-authored 92 publications receiving 3669 citations. Previous affiliations of Pinak B. Shah include Leonard Davis Institute of Health Economics & St. Elizabeth's Medical Center.
Papers
More filters
Journal ArticleDOI
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.
Brian W. McCrindle,Anne H. Rowley,Jane W. Newburger,Jane C. Burns,Anne F. Bolger,Michael H. Gewitz,Annette L. Baker,Mary Anne Jackson,Masato Takahashi,Pinak B. Shah,Tohru Kobayashi,Mei-Hwan Wu,Tsutomu Saji,Elfriede Pahl +13 more
TL;DR: These recommendations provide updated and best evidence-based guidance to healthcare providers who diagnose and manage Kawasaki disease, but clinical decision making should be individualized to specific patient circumstances.
Journal ArticleDOI
Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.
Douglas W. Losordo,Richard A. Schatz,Christopher J. White,James E. Udelson,Vimal Veereshwarayya,Vimal Veereshwarayya,Michelle Durgin,Michelle Durgin,Kian Keong Poh,Robert Weinstein,Marianne Kearney,Muqtada Chaudhry,Aaron Burg,Liz Eaton,Lindsay Heyd,Tina Thorne,Tina Thorne,Leon Shturman,Peter Hoffmeister,Ken Story,Victor Zak,Douglas Dowling,Jay H. Traverse,Rachel E. Olson,Janice Flanagan,Donata Sodano,Toshinori Murayama,Atsuhiko Kawamoto,Kengo Fukushima Kusano,Jill Wollins,Frederick G.P. Welt,Pinak B. Shah,Peter A Soukas,Takayuki Asahara,Timothy D. Henry +34 more
TL;DR: Efficacy parameters including angina frequency, nitroglycerine usage, exercise time, and Canadian Cardiovascular Society class showed trends that favored CD34+ cell–treated patients versus control subjects given placebo, providing evidence for feasibility, safety, and bioactivity.
Journal ArticleDOI
Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From the ACC's Interventional Council and SCAI.
Frederick G.P. Welt,Frederick G.P. Welt,Pinak B. Shah,Herbert D. Aronow,Anna E. Bortnick,Timothy D. Henry,Matthew W. Sherwood,Michael N. Young,Laura Davidson,Sabeeda Kadavath,Ehtisham Mahmud,Ajay J. Kirtane +11 more
TL;DR: Coronavirus disease 2019 (COVID-19) has placed an enormous strain on the health care systems of the nations where it has spread widely, with specific implications of the disease on practice in the catheterization laboratory.
Journal ArticleDOI
1-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Mitral Annular Calcification
Mayra Guerrero,Marina Urena,Dominique Himbert,Dee Dee Wang,Mackram F. Eleid,Susheel Kodali,Isaac George,Tarun Chakravarty,Moses Mathur,David Holzhey,Ashish Pershad,H. Kenith Fang,Daniel O'Hair,Noah Jones,Vaikom S. Mahadevan,Nicolas Dumonteil,Josep Rodés-Cabau,Nicolo Piazza,Enrico Ferrari,Daniel Ciaburri,Mohammed Nejjari,Augustin Delago,Paul Sorajja,Firas Zahr,Vivek Rajagopal,Brian Whisenant,Pinak B. Shah,Jan-Malte Sinning,Adam Witkowski,Hélène Eltchaninoff,Danny Dvir,Bena Martin,Guilherme F. Attizzani,Diego Felipe Gaia,Nagela S. V. Nunes,Amir-Ali Fassa,Faraz Kerendi,Gregory Pavlides,Vijay Iyer,Georges Kaddissi,Christian Witzke,James Wudel,Gregory J. Mishkel,Bryan Raybuck,Chi Wang,Ron Waksman,Igor F. Palacios,Alain Cribier,John G. Webb,Vinnie Bapat,Mark Reisman,Raj Makkar,Martin B. Leon,Charanjit S. Rihal,Alec Vahanian,William W. O'Neill,Ted Feldman +56 more
TL;DR: The TMVR in MAC Global Registry as mentioned in this paper is a multicenter registry that collects data on outcomes of transcatheter mitral valve replacement in patients with severe mitral annular calcification.
Journal ArticleDOI
Association Between Transcatheter Aortic Valve Replacement for Bicuspid vs Tricuspid Aortic Stenosis and Mortality or Stroke
Raj Makkar,Sung-Han Yoon,Martin B. Leon,Tarun Chakravarty,Michael Rinaldi,Pinak B. Shah,Eric Skipper,Vinod H. Thourani,Vasilis Babaliaros,Wen Cheng,Alfredo Trento,Sreekanth Vemulapalli,Samir R. Kapadia,Susheel Kodali,Michael J. Mack,Gilbert H.L. Tang,Tsuyoshi Kaneko +16 more
TL;DR: Patients with bic Suspid vs tricuspid aortic stenosis had no significant difference in 30-day or 1-year mortality but had increased 30- day risk for stroke and randomized trials are needed to adequately assess the efficacy and safety of TAVR.